American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 433-440 , September 2007

Warfarin Anticoagulation in Hemodialysis Patients: A Systematic Review of Bleeding Rates

  • Meghan J. Elliott, BSc

      Affiliations

    • Division of Nephrology, Queen’s University, Kingston, Ontario, Canada
    • ,
  • Deborah Zimmerman, MD, MSc

      Affiliations

    • Division of Nephrology, University of Ottawa, Ottawa, Ontario, Canada.
    • ,
  • Rachel M. Holden, MD

      Affiliations

    • Division of Nephrology, Queen’s University, Kingston, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to Rachel M. Holden, MD, 3048C Etherington Hall, Queen’s University, Kingston, Ontario, Canada K7L 2V6.

Received 1 January 2007 ,Accepted 15 June 2007.

References 

  1. Miller LM, Hopman WM, Garland JS, et al. Cardioprotective medication use in hemodialysis patients. Can J Cardiol. 2006;22:755–760
  2. US Renal Data System. Cardiovascular Special Studies (The National Institutes of Health). Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  3. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA. 2000;283:2008–2012
  4. Brautbar N, Menz CL, Winston MA, et al. Retroperitoneal bleeding in hemodialysis patients (A cause for morbidity and mortality). JAMA. 1978;239:1530–1531
  5. Inzelberg R, Neufeld MY, Reider I, et al. Nonsurgical treatment of subdural hematoma in a hemodialysis patient. Clin Neurol Neurosurg. 1989;91:85–89
  6. Milutinovich J, Follette WC, Scribner BH. Spontaneous retroperitoneal bleeding in patients on chronic hemodialysis. Ann Intern Med. 1977;86:189–192
  7. Quinn J, Oliver M, Hux J, Naimark D: Should hemodialysis patients with atrial fibrillation be anticoagulated? Canadian Society of Nephrology Annual Meeting, Calgary, Canada, 2005 (abstr)
  8. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol. 2002;13:2331–2337
  9. Leonard A, Shapiro FL. Subdural hematoma in regularly hemodialyzed patients. Ann Intern Med. 1975;82:650–658
  10. Mokrzycki MH, Jean-Jerome K, Rush H, et al. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int. 2001;59:1935–1942
  11. Obialo CI, Conner AC, Lebon LF. Maintaining patency of tunneled hemodialysis catheters: Efficacy of aspirin compared to warfarin. Scand J Urol Nephrol. 2003;37:172–176
  12. Uldall R, Besley ME, Thomas A, et al. Maintaining the patency of double-lumen Silastic jugular catheters for haemodialysis. Int J Artif Organs. 1993;16:37–40
  13. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  14. Webb A, Abdalla M, Russell GI. A protocol of urokinase infusion and warfarin for the management of the thrombosed haemodialysis catheter. Nephrol Dial Transplant. 2001;16:2075–2078
  15. Gultekin B, Ozkan S, Uguz E, et al. Valve replacement surgery in patients with end-stage renal disease: Long-term results. Artif Organs. 2005;29:972–975
  16. Coli L, Donati G, Cianciolo G, et al. Anticoagulation therapy for the prevention of hemodialysis tunneled cuffed catheter (TCC) thrombosis. J Vasc Access. 2006;7:118–122
  17. Harman GJS, Su Y, Day A, Pilkey RM: Gastrointestinal bleeding in hemodialysis patients. Canadian Society of Nephrology Annual Meeting, Calgary, Canada, 2005 (abstr)
  18. Nzerue M, Murray M: An analysis of treatment outcomes in patients with right atrial clots associated with central venous catheters (CVC). American Society of Nephrology Annual Meeting, San Diego, CA, 2006 (abstr)
  19. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003;16:245–256
  20. Ifudu O, Dulin AL. Pharmacokinetics and dialysability of warfarin in end-stage renal disease. Nephron. 1993;65:150–151
  21. Kinzner CL. Warfarin sodium (Coumadin) anticoagulant therapy for vascular access patency. ANNA J. 1998;25:195–203
  22. Smits JH, van der LJ, Blankestijn PJ, et al. Coagulation and haemodialysis access thrombosis. Nephrol Dial Transplant. 2000;15:1755–1760
  23. Traynor JP, Walbaum D, Woo YM, et al. Low-dose warfarin fails to prolong survival of dual lumen venous dialysis catheters. Nephrol Dial Transplant. 2001;16:645
  24. Twardowski ZJ. Stepwise anticoagulation with warfarin for prevention of intravenous catheter thrombosis. Hemodial Int. 2000;4:37–41
  25. Wright JR, Kalra PA. Ought dialysis patients with atrial fibrillation be treated with anticoagulants?. Int J Cardiol. 2006;87:139–141
  26. Lo DS, Rabbat CG, Clase CM. Thromboembolism and anticoagulant management in hemodialysis patients: A practical guide to clinical management. Thromb Res. 2006;118:385–395
  27. Biggers JA, Remmers AR, Glassford DM, et al. The risk of anticoagulation in hemodialysis patients. Nephron. 1977;18:109–113
  28. LeSar CJ, Merrick HW, Smith MR. Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg. 1999;189:73–79discussion, 79-81
  29. O’Shea SI, Lawson JH, Reddan D, et al. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg. 2003;38:541–548
  30. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol. 2003;87:135–139discussion, 139-141
  31. Zellweger M, Bouchard J, Raymond-Carrier S, et al. Systemic anticoagulation and prevention of hemodialysis catheter malfunction. ASAIO J. 2005;51:360–365
  32. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315–328
  33. Wiesholzer M, Harm F, Tomasec G, et al. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21:35–39

 Originally published online as doi:10.1053/j.ajkd.2007.06.017 on August 9, 2007.

PII: S0272-6386(07)00950-X

doi: 10.1053/j.ajkd.2007.06.017

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 433-440 , September 2007

Article Tools

* Image Usage & Resolution